Age-associated decline in IL-2 and IL-12 induction of LAK cell activity of human PBMC samples

Mechanisms of Ageing and Development

Volumn 90, Issue 3, 1996, Pages 209-222

  Kutza, Joseph ^a   Muraskoz, Donna M ^a  

^a DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

Cytotoxicity; IL 12; IL 2; Lymphokine activated killer cells; Natural killer cells; Peripheral blood mononuclear cells

Indexed keywords

ALPHA INTERFERON; INTERLEUKIN 12; INTERLEUKIN 2;

AGED; AGING; ARTICLE; CELL STRAIN K 562; CONTROLLED STUDY; CYTOTOXICITY; DAUDI CELL; HUMAN; HUMAN CELL; LYMPHOKINE ACTIVATED KILLER CELL; MONONUCLEAR CELL; NATURAL KILLER CELL; NORMAL HUMAN; PRIORITY JOURNAL; TARGET CELL;

EID: 0030607135     PISSN: 00476374     EISSN: None     Source Type: Journal    
DOI: 10.1016/0047-6374(96)01772-1     Document Type: Article

References (28)

1. [1] G. Trinchieri. Biology of natural killer cells. In F.J. Dixon (ed.), Advances in Immunology, Academic Press. San Diego, CA. 1989, pp. 187-376.
2. [2] E.T. Bloom, Natural killer cells, lymphokine-activated killer cells, and cytolytic T lymphocytes: compartmentalization of age-related changes in cytolytic lymphocytes? J. Geron. Biol. Sci. 49 (1994) B85-B92.
3. [3] J.H. Phillips and L.L. Lanier, Dissection of the lymphokine-activated killer phenomenon. Relative contribution of peripheral blood natural killer cells and T lymphocytes to cytolysis. J. Exp. Med. 164 (1986) 814-825.
4. [4] E.A. Grimm, A. Mazumder, H.Z. Zhang and S.A. Rosenberg, Lymphokine-activated killer cell phenomenon. J. Exp. Med. 155 (1982) 1823-1841.
5. [5] G. Trinchieri, M. Matsumoto-Kobayashi, S.C. Clark, J. Seehra, L. London and B. Perussia, Response of resting human peripheral blood natural killer cells to interleukin-2. J. Exp. Med. 160 (1984) 1147-1169.
6. [6] M.R. Anderson, H.M. Sassenfeld and M.B. Widmer, Interleukin-7 enhances cytolytic T lymphocytes generation and induces lymphokine-activated killer cells from human peripheral blood. J. Exp. Med. 172 (1990) 577-587.
7. [7] H. Stotter, M.C. Custer, E.S. Bolton, L. Guedex and M.T. Lotze. IL-7 induces human lymphokine-activated killer cell activity and is regulated by IL-4. J. Immunol. 146 (1991) 150-155.
8. + NK cells. J. Immunol. 148 (1992) 2429-2436.
9. [9] M.J. Robertson, R.J. Soiffer, S.F. Wolf et al., Response of human natural killer (NK) cells to NK cell stimulatory factor (NKSF): cytolytic activity and proliferation of NK cells are differentially regulated by NKSF. J. Exp. Med. 175 (1992) 779-788.
10. [10] C.D. Platsoucas, F.E. Fox, E. Oleszak et al., Regulation of natural killer cytotoxicity by recombinant alpha interferons. Augmentation by IFN-alpha-7 an interferon similar to IFN-alpha J. Anticancer Res. 9 (1989) 849-858.
11. [11] T.M. Ellis, R.S. McKenzie, P.E. Simms, B.A. Helfrich and R.I. Fisher, Induction of human lymphokine-activated killer cells by IFN-α and IFN-γ. J. Immunol. 143 (1989) 4282-4286.
12. [12] J. Kutza and D.M. Murasko, Effects of aging on natural killer cell activity and activation by interleukin-2 and IFN-α. Cell. Immunol. 155 (1994) 195-204.
13. [13] T.J. Eberlein, M. Rosenstein and S.A. Rosenberg, Regression of a disseminated syngeneic solid tumor by systemic transfer of lymphoid cells expanded in interleukin-2. J. Exp. Med. 156 (1982) 385-397.
14. [14] A. Mazumder and S.A. Rosenberg, Successful immunotherapy of natural killer-resistant established pulmonary melanoma metastases by the intravenous adoptive transfer of syngeneic lymphocytes activated in vitro by interleukin-2. J. Exp. Med. 159 (1984) 495-507.
15. [15] S.A. Rosenberg, M.T. Lotze, L.M. Muul et al., Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N. Eng. J. Med. 313 (1985) 1485-1492.
16. [16] J. Kutza, D. Kaye and D.M. Murasko, Basal natural killer cell activity of young versus elderly humans. J. Gerontol. Biol. Sci. 50A (1995) B110-B116.
17. 51Cr labelled allogeneic target cells in vitro: inhibition by isoantibody and by drugs. Immunology 14 (1968) 181-196.
18. [18] J. Bubenik, B. Cinader, M. Indrovà, S.W. Koh and C.T. Chou, Lymphokine-activated killer (LAK) cells: I. Age dependent decline of LAK cell mediated cytotoxicity. Immunol. Lett. 16 (1987) 113-119.
19. [19] S.N. Bykovskaya, I.F. Abronina, T.A. Kupriyanova and J. Bubenik, Down regulation of LAK cell-mediated cytotoxicity: cancer and aging. Biomed. Pharmacother. 44 (1990) 333-338.
20. [20] M. Provinciali, G. DiStefano and N. Fabris. Evaluation of lymphokine-activated killer cell development in young and old healthy humans. Nat. Immun. 14 (1995) 134-144.
21. [21] D.M. Murasko, P. Weiner and D. Kaye. Decline in mitogen induced proliferation in the increasing age. Clin. Exp. Immunol. 70 (1987) 440-448.
22. [22] M.J. Robertson, M.A. Califiuti, T.J. Manley, H. Levine and J. Ritz, Human natural killer cell adhesion moleules. Differential expression after activation and participation in cytolysis. J. Immunol. 145 (1990) 3194-3201.
23. [23] M. Patarroyo, J. Prieto, J. Rincon et al. Leukocyte-cell adhesion: a molecular process fundamental in leukocyte physiology. Immunol. Rev. 114 (1990) 67-108.
24. [24] H. Umehara, A. Takashima, Y. Minami and E.T. Bloom, Signal transduction via phosphorylated adhesion molecule, LFA-1 β (CD18), is increased by culture of natural killer (NK) cells with interleukin (IL)-2 in the generation of lymphokine activated killer (LAK) cells. Inter. Immunol. 5 (1993) 19-27.
25. [25] D. Zarcone, O. Viarle, G. Cerruti et al. Antibodies to adhesion molecules inhibit the lytic function of MHC-unrestricted cytotoxic cells by preventing their activation. Cell. Immunol. 143 (1992) 389-404.
26. [26] A. Mäenpàä. J. Jääskeläinen, O. Carpen, M. Patarroyo and T. Timonen, Expression of integrins and other adhesion molecules on NK cells: impact of IL-2 on short and long term cultures. Int. J. Cancer 53 (1993) 850-855.
27. [27] A. Eisenthal, Y. Skornick, I. Ron, V. Zakuth and S. Chaitchik, Phenotypic and functional profile of peripheral blood mononuclear cells isolated from melanoma patients undergoing combined immunotherapy and chemotherapy. Cancer Immunol. Immunotherap. 37 (1993) 367-372.
28. [28] I.G. Ron, Y. Murdisk, A. Eisenthal, Y. Skornick, M.J. Inbar and S. Chaitchik. A phase II study of combined administration of dacarbazine and carboplatin with home therapy of recombinant interleukin-2 and interferon-alpha 2a in patients with advanced malignant melanoma. Cancer Immunol. Immunotherap. 38 (1994) 379-384.